文献速递哮喘呼吸道感染

奥马珠单抗对鼻病毒感染、疾病及哮喘急性发作的影响

Effects of Omalizumab on Rhinovirus Infections, Illnesses, and Exacerbations of Asthma.
PubMed 文献 · Am J Respir Crit Care Med · 2017-01-01

PROSE研究纳入8个美国城市低收入社区的过敏性哮喘儿童(6-17岁,n=478),对按指南治疗组(n=89)与加用奥马珠单抗组(n=259)进行病毒学分析。奥马珠单抗缩短鼻病毒感染持续时间(11.2天 vs 12.4天,P=0.03)、降低病毒排出峰值0.4 log单位,并减少鼻病毒疾病频率(风险比0.64,95%CI 0.49-0.84)。

要点

  • 奥马珠单抗可缩短过敏性哮喘儿童的鼻病毒感染持续时间并降低病毒排出。
  • 奥马珠单抗使鼻病毒疾病风险降低(风险比0.64,95%CI 0.49-0.84)。
  • 鼻病毒检出与哮喘急性发作相关,鼻病毒C与A型关联更强。

核心结论

  • 在过敏性哮喘儿童中,奥马珠单抗治疗缩短鼻病毒感染持续时间、减少病毒排出并降低鼻病毒疾病风险。
  • 这些发现提供直接证据表明阻断IgE可降低对鼻病毒感染和疾病的易感性。

研究设计与样本

  • PROSE(Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations)研究,分析8个美国城市低收入普查区6-17岁过敏性哮喘儿童(n=478)。
  • 病毒学分析比较指南基础哮喘治疗组(n=89)与加用奥马珠单抗组(n=259)。
  • 2012或2013年秋季90天期间每周采集鼻黏液检测鼻病毒,记录呼吸道症状与哮喘急性发作。
  • 按治疗组用Poisson回归计算调整后疾病率(每份样本的疾病数)。

主要发现

  • 鼻病毒在171份急性发作样本中检出97份(57%),在5,959份非急性发作样本中检出2,150份(36%)(OR 2.32;P<0.001)。
  • 急性发作与鼻病毒C检出(OR 2.85;P<0.001)和鼻病毒A检出(OR 2.92;P<0.001)显著相关,与鼻病毒B关联较弱(OR 1.98;P=0.019)。
  • 奥马珠单抗缩短鼻病毒感染持续时间(11.2天 vs 12.4天;P=0.03)。
  • 奥马珠单抗使鼻病毒排出峰值降低0.4 log单位(95%CI -0.77至-0.02;P=0.04)。
  • 奥马珠单抗降低鼻病毒疾病频率(风险比0.64;95%CI 0.49-0.84)。

临床怎么用

  • 对过敏性哮喘儿童,奥马珠单抗除控制过敏炎症外,可能减少鼻病毒感染及其诱发的疾病。
  • 鼻病毒检出与急性发作相关,提示秋季应关注鼻病毒监测与防控。

局限性

  • 病毒学分析仅覆盖随机分组中的部分儿童(指南治疗组n=89,奥马珠单抗组n=259),非全部478例。
  • 观察期仅为2012或2013年秋季90天,结果的外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Allergic inflammation has been linked to increased susceptibility to viral illnesses, but it is unclear whether this association is causal. OBJECTIVES: To test whether omalizumab treatment to reduce IgE would shorten the frequency and duration of rhinovirus (RV) illnesses in children with allergic asthma. METHODS: In the PROSE (Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations) study, we examined children with allergic asthma (aged 6-17 yr; n = 478) from low-income census tracts in eight U.S. cities, and we analyzed virology for the groups randomized to treatment with guidelines-based asthma care (n = 89) or add-on omalizumab (n = 259). Weekly nasal mucus samples were analyzed for RVs, and respiratory symptoms and asthma exacerbations were recorded over a 90-day period during the fall seasons of 2012 or 2013. Adjusted illness rates (illnesses per sample) by treatment arm were calculated using Poisson regression. MEASUREMENTS AND MAIN RESULTS: RVs were detected in 97 (57%) of 171 exacerbation samples and 2,150 (36%) of 5,959 nonexacerbation samples (OR, 2.32; P < 0.001). Exacerbations were significantly associated with detection of rhinovirus C (OR, 2.85; P < 0.001) and rhinovirus A (OR, 2.92; P < 0.001), as well as, to a lesser extent, rhinovirus B (OR, 1.98; P = 0.019). Omalizumab decreased the duration of RV infection (11.2 d vs. 12.4 d; P = 0.03) and reduced peak RV shedding by 0.4 log units (95% confidence interval, -0.77 to -0.02; P = 0.04). Finally, omalizumab decreased the frequency of RV illnesses (risk ratio, 0.64; 95% confidence interval, 0.49-0.84). CONCLUSIONS: In children with allergic asthma, treatment with omalizumab decreased the duration of RV infections, viral shedding, and the risk of RV illnesses. These findings provide direct evidence that blocking IgE decreases susceptibility to RV infections and illness. Clinical trial registered with www.clinicaltrials.gov (NCT01430403).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Esquivel A, Busse WW, Calatroni A, et al. Effects of Omalizumab on Rhinovirus Infections, Illnesses, and Exacerbations of Asthma. Am J Respir Crit Care Med. 2017. PMID: 28608756. doi:10.1164/rccm.201701-0120OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。